Global Human Chorionic Gonadotropin Market Projected to Grow at 8.2% CAGR, Reaching $1.41 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Human Chorionic Gonadotropin Industry Market Size Be by 2025?
The market encompassing human chorionic gonadotropin has experienced robust expansion recently, projected to increase its valuation from $0.95 billion in 2024 to $1.02 billion in 2025, reflecting an 8.4% compound annual growth rate. This upward trajectory during the past period stems from several factors, including the heightened incidence of hypogonadism observed within the aging demographic, heightened consciousness regarding HCG among both medical practitioners and the general public, the growing appeal of fertility travel, an expanding elderly population base, and better healthcare infrastructure coupled with enhanced financial accessibility to medical services.

What's the Long-Term Growth Forecast for the Human Chorionic Gonadotropin Market Size Through 2029?
Anticipation surrounds the human chorionic gonadotropin sector, projecting substantial expansion in the forthcoming years, with its market valuation projected to reach $1.41 billion by 2029, fueled by an annual average growth rate (CAGR) of 8.2%; this upswing is primarily driven by a greater occurrence of infertility issues globally, the escalating spread of polycystic ovary* syndrome, the rise in female fertility challenges, and the heightened application of HCG within the realm of veterinary pharmaceuticals, while key developments shaping this period involve progress in identifying pregnancy early, the creation of novel medicinal preparations, the incorporation of new technologies, greater emphasis placed on research endeavors, and continuous product novelty.

View the full report here:
https://www.thebusinessresearchcompany.com/report/human-chorionic-gonadotropin-global-market-report

What Are the Key Growth Drivers Fueling the Human Chorionic Gonadotropin Market Expansion?
The escalating incidence of infertility is anticipated to be the impetus behind the expansion of the human chorionic gonadotropin market moving ahead. Infertility is characterized by the failure to achieve pregnancy following a minimum of twelve months involving regular, unprotected sexual activity. This rising infertility trend is linked to various contributors, including a tendency toward later parenthood, shifts in daily living patterns, exposure to environmental elements, and underlying health issues faced by growing numbers of individuals and couples struggling with conception. Human chorionic gonadotropin (hCG) plays a role in fertility therapies by triggering egg release in females and bolstering testosterone creation in males, thereby aiding the discharge of ova and enhancing the likelihood of successful conception. To illustrate the scale of this issue, data shared by the World Health Organization, an international body headquartered in Switzerland, indicated in April 2023 that approximately 17.5 percent of adults globally, equating to about one in every six persons, were impacted by infertility, underscoring the significant requirement for enhanced availability of affordable, quality reproductive healthcare for those requiring it; consequently, the mounting global infertility rates are fueling the expansion observed in the human chorionic gonadotropin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18638&type=smp

What Are the Key Trends Driving Human Chorionic Gonadotropin Market Growth?
Leading entities within the human chorionic gonadotropin sector are concentrating efforts on the creation of novel merchandise, notably pregnancy detection kits, aiming to boost the precision of diagnoses, elevate results for patients, and broaden their presence across the market. These kits serve as instruments to ascertain pregnancy status by identifying human chorionic gonadotropin (hCG) within the body. A specific illustration involves Proov, an American manufacturer of medical apparatus, which, in June 2022, released advanced hCG tests engineered for prompt pregnancy identification, allowing females to confirm gestation as early as six days before a missed menstrual cycle; these diagnostic tools operate by recognizing hCG presence in urine and boast a superior reliability exceeding 99 percent, thereby furnishing women with an easily obtained and trustworthy means to ascertain their pregnancy condition sooner than conventional methods permit, thus facilitating proactive choices about their reproductive well-being.

How Is the Human Chorionic Gonadotropin Market Segmented?
The human chorionic gonadotropinmarket covered in this report is segmented -

1) By Technology: Natural Source Extraction; Recombinant Technology
2) By Therapeutic Area: Female Infertility Treatment; Oligospermic Treatment; Male Hypogonadism; Other Therapeutic Areas
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Fertility Clinics; Research Institutions; Other End Users

Subsegments:
1) By Natural Source Extraction: Extraction From Pregnant Women's Urine; Extraction From Animal Sources
2) By Recombinant Technology: Recombinant Hcg; Recombinant Hcg For Therapeutic Use; Recombinant Hcg For Diagnostic Applications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18638&type=smp

Which Companies Are Leading the Charge in Human Chorionic Gonadotropin Market Innovation?
Major companies operating in the human chorionic gonadotropin market are Pfizer Inc., Merck & Co Inc., Novartis AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Janssen Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Limited, Menarini Group, Cipla Limited, Hikma Pharmaceuticals plc, Ferring Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Lupin Limited, Shenzhen Hepalink Pharmaceutical Group Co. Ltd., Scripps Laboratories Inc., Aspen Pharmacare Holdings Limited, Corona Remedies Pvt Ltd., Sanzyme Private Limited, Biocare Medical LLC, Lee BioSolutions Inc., MyBioSource Inc.

Which Regions Are Leading the Global Human Chorionic Gonadotropin Market in Revenue?
North America was the largest region in the human chorionic gonadotropin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human chorionic gonadotropin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18638

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.